Oral candidiasis: A review

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 2, Issue 4, 2010, Pages 36-41

  Dangi, Yuvraj Singh ^a   Soni, Murari Lal ^a   Namdeo, Kamta Prasad ^a  

^a GURU GHASIDAS UNIVERSITY   (India)

Author keywords

Candidiasis

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT; CLOTRIMAZOLE; ECHINOCANDIN; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; NYSTATIN; TRIAZOLE DERIVATIVE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AIDS PATIENT; ASPERGILLUS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CD4 LYMPHOCYTE COUNT; CROSS RESISTANCE; DENTAL PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOPATHOLOGY; INFECTION PREVENTION; INFECTION SENSITIVITY; MORBIDITY; MORTALITY; PATIENT EDUCATION; RECURRENT INFECTION; REVIEW; THRUSH;

EID: 83655183055     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Greenspan D. Treatment of oral candidiasis in HIV infection. Oral Surg Oral Med Oral Pathol 1994;78:211-5.
2. MacPhail LA, Hilton JF, Dodd CL, Greenspan D. Prophylaxis with nystatin pastilles for HIV-associated oral candidiasis. J Acquir Immune Defic Syndr 1996;12:470-6.
3. Pons V, Greenspan D, Lozada-Nur F, MacPhail L, Gallant JE, Tunkel A, et al. Oropharyngeal candidiasis in patients with AIDS: randomized comparison of fluconazole versus nystatin oral suspensions. Clin Infect Dis 1997;24:1204-7.
4. Scully C, el Kabir M, Samaranyake LP. Candida and oral candidosis: A review. Crit Rev Oral Biol Med 1994;5(2):125-157.
5. Challacombe SJ. Immunologic aspects of oral candidiasis. Oral Surg Oral Med Oral Pathol 1994;78(2):202-210.
6. Stevens DA, Greene SI, Lang OS. Thrush can be prevented in patients with acquired immunodeficiency syndrome and the acquired immunodeficiency syndrome-related complex. Randomized, double-blind, placebo-controlled study of 100-mg oral fluconazole daily. Arch Intern Med 1991;151:2458-64
7. Schuman P, Capps L, Peng G, Vazquez J, El-Sadr W, Goldman AI, et al. Weekly fluconazole for the prevention of mucosal candidiasis in women with HIV infection. A randomized, double-blind, placebo-controlled trial. Terry Beirn Community Programs for Clinical Research on AIDS. Ann Intern Med 1997;126:689-96
8. Hunter KD, Gibson J, Lockhart P, Pithie A, Bagg J. Fluconazoleresistant Candida species in the oral flora of fluconazole-exposed HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1998;85:558-64.
9. Tumbarello M, Tacconelli E, Caldarola G, Morace G, Cauda R, Ortona L. Fluconazole resistant oral candidiasis in HIV-infected patients. Oral Dis 1997;3(Suppl 1):S110-2.
10. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, et al. Epidemiology of oral candidiasis in HIV- infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994;97:339-46.
11. Clark TA, Hajjeh RA. Recent trends in the epidemiology of invasive mycoses. Curr Opin Infect Dis 2004;17:511-5.
12. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: cur rent epidemiological trends. Clin Infect Dis 2006;43(Suppl. 1):S3-14.
13. Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: epidemiology and resistance. Int J Antimicrob Agents 2006;27:359-66
14. Hsueh PR, Teng LJ, Yang PC, Ho SW, Luh KT. Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. Microb Drug Resist 2003;8:311-9.
15. Pfaller MA, Diekema DJ. Rare and emerging opportunistic fungal pathogens: concern for resistance beyond Candida albicans and Aspergillus fumigatus. J Clin Microbiol 2004;42:4419-31.
16. Hajjeh RA, Sofair AN, Harrison LH, et al. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004;42:1519-27.
17. Kuhn DM, Mikherjee PK, Clark TA, et al. Candida parapsilosis characterization in an outbreak setting. Emerg Infect Dis 2004;10:1074-81.
18. Sarvikivi E, Lyytikainen O, Soll DR, et al. Emergence of fluconazole resistance in a Candida parapsilosis strain that caused infections in a neonatal intensive care unit. J Clin Microbiol 2005;43:2729-35.
19. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA. Candida glabrata fungemia: experience in a tertiary care center. ClinInfect Dis 2005;41:975-81.
20. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000;181:309-16.
21. Pfaller MA, Diekema DJ, Rinaldi MG, et al. Results from the ARTEMIS DISK global antifungal surveillance study: a 6.5-year analysis of the worldwide susceptibility of Candida and other yeasts species to fluconazole and voriconazole using standardized disk diffusion testing. J Clin Microbiol 2005;43:5848-59.
22. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United tates during 1989-1999. Clin Infect Dis 2002;35:627-30.
23. Hope W, Morton A, Eisen DP. Increase in prevalence of nosocomial non-Candida albicans candidaemia and the association of Candida krusei with fluconazole use. J Hosp Infect 2002; 50:56-65.
24. Baddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32:1319-24.
25. Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909-17.
26. Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis: disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79:250-60
27. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet 2005;366:1013-25.
28. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-66.
29. Comillet A, Camus C, Nimubona S, et al. Comparison of epidemiological, clinical, and biological features of invasive aspergillosis in neutropenic and nonneutropenic patients: a 6- year survey. Clin Infect Dis 2006;43:577-84.
30. Roden MM, Zaoutis T, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005;41:634-53.
31. Spellberg B, Edwards Jr J, Ibrahim A. Novel perspectives on mucormycosis: pathophysiology, presentation, and management. Clin Microbiol Rev 2005;18:556-69
32. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 2005;191:1350-60.
33. Imhof A, Balajee A, Fredricks D, Englund J, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743-6.
34. Skoglund A, Sunzel B, Lerner UH. Comparison of three test methods used for the diagnosis of candidiasis. Scand J Dent Res 1994;102(5): 295-298
35. Fenlon MR, Sherriff M. Prevalence of denture related stomatitis in patients attending a dental teaching hospital for provision of replacement complete dentures. J Ir Dent ssoc 1998;44(1):9-10.
36. Evans J, Orme DS, Sedgwick ML, Youngs GR. Treating oral candidiasis: Potentially fatal. Br Dent J 1997;182(12):452.
37. Ohman SC, Dahlén G, Möller A, Ohman A. Angular cheilitis: A clinical microbial study. J Oral Pathol 1986;15(4):213-217.
38. Muzyka BC, Glick M. A review of oral fungal infections and appropriate therapy. J Am Dent Assoc 1995;126(1):63-72.
39. Blomgren J, Berggren U, Jontell M. Fluconazole versus nystatin in the treatment of oral candidosis. Acta Odontol Scand 1998;56(4):202-205.
40. Eisen D, Lynch DP. The Mouth: Diagnosis and Treatment. St. Louis, MO: Mosby; 1998:128-135, 286-287.
41. Webb BC, Thomas CJ, Willcox MD, et al. Candida-associated denture stomatitis. Aetiology and management: A review. Part 3. Treatment of oral candidosis. Aust Dent J 1998;43(3):160-166.
42. Chau VB, Saunders TR, Pimsler M, Elfring DR. In-depth disinfection of acrylic resins. J Prosthet Dent 1995;74(3):309-313.
43. Granata JS, Staffanou RS. Evaluation of a new denture bath solution.J Prosth Dent 1991;66(6):790-791.
44. Dixon DL, Breeding LC, Faler TA. Microwave disinfection of denture base material colonized with Candida albicans. J Prosthet Dent 1999; 81(2):207-214.
45. Bates DW, Su L, Yu DT, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 689-93
46. Poirier JM, Cheymol G. Optimisation of itraconazole therapy using target drug concentrations. Clin Pharmacokinet 1998; 35: 461-73
47. Manavathu EK, Cutright JL, Chandrasekar PH. Organismdependent fungicidal activities of azoles. Antimicrob Agents Chemother 1998; 42: 3018-21
48. Jhonson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-7.
49. Keating GM. Posaconazole. Drugs 2005; 65: 1553-67.
50. Leveque D, Niviox Y, Jehl F, Herbrecht R. Clinical pharmacokinetics of voriconazole. Int J Antimicrob Agents 2006;27:274-84.
51. Torres HA, Hachem RY, Chemaly RF, Kantoyiannis DP, Raad I. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005;5:775-8
52. Lutsar I, Roffey S, Troke P. Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients. Clin Infect Dis 2003;37:728-32
53. Groll AH, Kolve H. Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy. Eur J Clin Microbiol Infect Dis 2004;23:256-70
54. Barchiesi F, Arzeni D, Fothergill AW, et al. In vitro activities of the new antifungal triazole SCH 56592 against common and emerging yeast pathogens. Antimicrob Agents Chemother 2000;44:226-9.
55. Hsueh PR, Lau YJ, Chuang YC, et al. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother 2005;49:512-7.
56. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 2001;39:954-8.
57. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001;45:2151-3.
58. Safdar A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis 2002;34:1415-7.
59. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ. In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp. Antimicrob Agents Chemother 2002;46:1723-7.
60. Gonzalez GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol 2005;43:281-4.
61. Keating GM, Figgitt DP. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs 2003;63:2235-63.
62. Denning DW. Echinocandin antifungal drugs. Lancet 2003;362: 1142-51
63. Green LJ, Marder P, Mann LL, Chio LC, Current WL. LY303366 exhibits rapid and potent fungicidal activity in flow cytometric assays of yeast viability. Antimicrob Agents Chemother 1999;43:830-5.
64. Chandrasekar PH, Sobel JD. Micafungin: a new echinocandin. Clin Infect Dis 2006;42:1171-8.
65. Vazquez JA, Sobel JD. Anidulafungin: a novel echinocandin. Clin Infect Dis 2006;43:215-22.
66. Denning DW. Echinocandin antifungal drugs. Lancet 2003;362: 1142-51.
67. Pfaller MA, Diekema DJ, Messer SA, Hollis RJ, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003; 47: 1068-71.
68. Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44:57-62.
69. Carver PL. Micafungin. Ann Pharmacother 2004;38:1707-21.
70. Gallis HA, Drew RH, Pickard WV. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329
71. Bennett JE, Dismukes WE, Duma RJ et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 30I:126-131.
72. Dismukes WE, Cloud G, Gallis HA et al. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for 4 as compared with 6 weeks. N Engl J Med 1987; 317:334-341.
73. Saag MS, Powderly WG, Cloud GA et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS associated cryptococcal meningitis. N Engl J Med 1992; 326: 83-89.
74. Van Der Horst C, Saag M, Cloud G et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med 1997; 337: 15-21.
75. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20:1526-1530.
76. Anaissie E, Gokaslan A, Hachem R et al. Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis. 1992; 15(5): 781-787.
77. Dromer F, Dupont B. The increasing problem of fungal infections in the immunocompromised host.J Mycologie Medicale 1996; 6: I-6.
78. Samonis G, Bafaloukos D. Fungal infections in cancer patients: an escalating problem. In Vivo 1992; 6(2): 183-193.